MATTHEW FOWLER: Open Payments
NPI 1053943688 · NAMPA, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$225 in 12 payments from 7 companies in 2025. Trend: 2023 $953 · 2024 $567 · 2025 $225
Food & beverage: $225
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 3 | $63 |
| Teva Pharmaceuticals USA, Inc. | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Corium, LLC | 2 | $28 |
| Neurocrine BioSciences, Inc. | 1 | $23 |
| E.R. Squibb & Sons, L.L.C. | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
Products named: Auvelity, REXULTI, Azstarys, INGREZZA, AUSTEDO XR, UZEDY, COBENFY, Qelbree.
Industry payments across ID — which companies pay providers there.
